Biogen Inc. (BIIB) vs Quest Diagnostics Incorporated (DGX)
BIIB leads on 9 of 15 compared metrics.
A side-by-side comparison of Biogen Inc. and Quest Diagnostics Incorporated across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of July 25, 2026. The ● marks the stronger figure on each row (cheaper multiple, higher margin/return).
BIIB
Biogen Inc.
$202.19HealthcareAt close: Jul 24, 2026, 4:00 PM ET
DGX
Quest Diagnostics Incorporated
$227.86HealthcareAt close: Jul 24, 2026, 4:00 PM ET
Total return — BIIB vs DGX
growth of $100 · dividends reinvested · last 30yBIIB +4826.5%DGX +9113.7%DGX compounded faster
BIIB DGX
BIIB vs DGX: by the numbers
- •BIIB is the larger company ($29.85B vs $25.15B market cap).
- •BIIB trades at the lower earnings multiple (21.65 vs 24.19 P/E).
- •BIIB converts more revenue to profit (13.92% vs 12.02% net margin).
- •DGX grew revenue faster over the past five years (0.89% vs -4.80% CAGR).
- •DGX pays a dividend (1.46% yield) while BIIB does not currently pay one.
Which is better, BIIB or DGX?
Metric tally: BIIB 9 · DGX 6It depends on what you're optimizing for:
ValueBIIB(lower P/E)
GrowthDGX(faster 5Y revenue CAGR)
QualityDGX(higher ROIC)
Metrics side by side
Valuation
| Metric | BIIB | DGX |
|---|---|---|
| P/E ratio | 21.65● | 24.19 |
| Forward P/E | 15.59● | 20.67 |
| P/S ratio | 3.04 | 2.21● |
| P/B ratio | 1.61● | 3.40 |
| PEG ratio | — | 1.43 |
| EV / EBITDA | 13.65● | 16.27 |
| FCF yield | 8.74%● | 5.29% |
Profitability
| Metric | BIIB | DGX |
|---|---|---|
| Gross margin | 69.77%● | 33.15% |
| Operating margin | 15.65%● | 14.14% |
| Net margin | 13.92%● | 12.02% |
| ROE | 7.36% | 18.49%● |
| ROIC | 6.62% | 8.43%● |
Dividends
| Metric | BIIB | DGX |
|---|---|---|
| Dividend yield | — | 1.46% |
| Payout ratio | — | 37.43% |
Growth (annualized)
| Metric | BIIB | DGX |
|---|---|---|
| Revenue CAGR (5Y) | -4.80% | 0.89%● |
| EPS CAGR (5Y) | -18.67% | -3.65%● |
| FCF CAGR (5Y) | -3.59%● | -9.08% |
| Total return CAGR (5Y) | -9.07% | 12.48%● |
Frequently asked
- Which is better, BIIB or DGX?
- It depends on your goal. value: BIIB (lower P/E); growth: DGX (faster 5Y revenue CAGR); quality: DGX (higher ROIC). Across all compared metrics, BIIB leads 9 to 6.
- Is BIIB or DGX cheaper?
- On trailing earnings, BIIB is cheaper: BIIB trades at a 21.65 P/E and DGX at 24.19.
- Which has grown faster, BIIB or DGX?
- Over the past five years, DGX grew revenue faster — BIIB at a -4.80% CAGR versus DGX at 0.89%.
- Does BIIB or DGX pay a bigger dividend?
- DGX pays a dividend (1.46% yield) while BIIB does not currently pay one.
- Is BIIB or DGX more profitable?
- BIIB runs the higher net margin — BIIB at 13.92% versus DGX at 12.02%.
- Which has been the better investment, BIIB or DGX?
- Over the past 10-year, DGX delivered the higher annualized total return — BIIB at -3.47% versus DGX at 12.55%. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Biogen P/E ratioQuest Diagnostics P/E ratioBiogen dividend yieldQuest Diagnostics dividend yieldBiogen ROEQuest Diagnostics ROEBiogen operating marginQuest Diagnostics operating marginBiogen revenue growthQuest Diagnostics revenue growthBiogen free cash flowQuest Diagnostics free cash flow
Biogen & Quest Diagnostics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified July 25, 2026.